Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/1/2025 | $720.00 | Neutral | UBS |
8/5/2025 | $545.00 → $785.00 | Buy | BTIG Research |
7/1/2025 | $625.00 | Buy | Jefferies |
12/2/2024 | $500.00 | Outperform | Leerink Partners |
7/25/2024 | $580.00 | Buy | BTIG Research |
1/30/2024 | $525.00 | Overweight → Neutral | Piper Sandler |
12/7/2023 | $602.00 | Outperform | Exane BNP Paribas |
12/4/2023 | Neutral → Buy | Cleveland Research |
UBS initiated coverage of IDEXX Labs with a rating of Neutral and set a new price target of $720.00
BTIG Research reiterated coverage of IDEXX Labs with a rating of Buy and set a new price target of $785.00 from $545.00 previously
Jefferies initiated coverage of IDEXX Labs with a rating of Buy and set a new price target of $625.00
Former Modernizing Medicine sales leader joins Bonsai to accelerate growth of its agentic AI platform for healthcare practices. Bonsai Health, the agentic AI platform automating complex healthcare workflows, today announced that Rick Trefzger has joined the company as Chief Revenue Officer (CRO). Trefzger joins Bonsai after nearly 11 years at Modernizing Medicine (ModMed), where he was an early employee and served as vice president of sales, helping scale the company into the leading specialty-specific EHR platform serving dermatology, ophthalmology, orthopedics, gastroenterology, and other core specialties. During his tenure, ModMed grew into one of the most widely adopted specialty te
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 third quarter financial results for Monday, November 3, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Karen Peacock to the Company's Board of Directors, effective October 6, 2025. "We are extremely pleased to welcome Karen to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Karen is a highly accomplished executive with deep B2B, SaaS software and AI experience gained through building and running software and technology companies at various lifecycle stages. We are confident that her extensive professional experience and skills will complement those of our other Board members and contribute to our Board's overal
8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
10-Q - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
3 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)
SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)
SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)
Former Modernizing Medicine sales leader joins Bonsai to accelerate growth of its agentic AI platform for healthcare practices. Bonsai Health, the agentic AI platform automating complex healthcare workflows, today announced that Rick Trefzger has joined the company as Chief Revenue Officer (CRO). Trefzger joins Bonsai after nearly 11 years at Modernizing Medicine (ModMed), where he was an early employee and served as vice president of sales, helping scale the company into the leading specialty-specific EHR platform serving dermatology, ophthalmology, orthopedics, gastroenterology, and other core specialties. During his tenure, ModMed grew into one of the most widely adopted specialty te
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Karen Peacock to the Company's Board of Directors, effective October 6, 2025. "We are extremely pleased to welcome Karen to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Karen is a highly accomplished executive with deep B2B, SaaS software and AI experience gained through building and running software and technology companies at various lifecycle stages. We are confident that her extensive professional experience and skills will complement those of our other Board members and contribute to our Board's overal
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. "We are excited to welcome Jay to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Jay is an accomplished executive who brings extensive strategic thinking and financial leadership experience, along with investor perspective, from his tenure leading State Street during a period of global growth and technological transformation. Given his substantial public company board and corporate governance experience and his unique backgro
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 third quarter financial results for Monday, November 3, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen
Achieves second quarter revenue growth of 11% as reported and 9% organic, supported by CAG Diagnostics recurring revenue growth of 9% as reported and 7% organic. Advances IDEXX's innovation agenda and continues strong global commercial execution, resulting in record quarterly instrument placements, including nearly 2,400 IDEXX inVue Dx™ placements. Delivers EPS of $3.63, an increase of 49% as reported, and 17% on a comparable basis, net of $0.56 EPS growth benefit from comparison to prior year period discrete litigation expense accrual, and including $0.07 benefit from a discrete tax reserve release. Increases 2025 revenue guidance to $4,205 million - $4,280 million, an increas
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 second quarter financial results for Monday, August 4, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen